PARADIGM BIOPHARMACEUTICALS Aktie

>PARADIGM BIO Performance

1 Woche: +1,4%

1 Monat: -6,9%

3 Monate: -17,2%

6 Monate: -24,4%

1 Jahr: -17,7%

laufendes Jahr: -17,2%

>PARADIGM BIO Aktie

Name:

PARADIGM BIOPHARMACEUTICALS

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000PAR5 / A12FJ4

Symbol/ Ticker:

P86 (Frankfurt)

Kürzel:

FRA:P86, ETR:P86, P86:GR

Index:

Webseite:

https://paradigmbiopharma..

Profil:

Paradigm Biopharmaceuticals Limited is an Australian biotechnology company specializing in the research and development of therapeutic products for human use. Headquartered in Melbourne, the company's primary focus is on drug repurposing, where exist..
>Volltext..

Marktkapitalisierung:

74.5 Mio. EUR

Unternehmenswert:

66.5 Mio. EUR

Umsatz:

0.04 Mio. EUR

EBITDA:

-22.24 Mio. EUR

Nettogewinn:

-20.86 Mio. EUR

Gewinn je Aktie:

-0.05 EUR

Schulden:

0.33 Mio. EUR

Liquide Mittel:

8.48 Mio. EUR

Operativer Cashflow:

-15.85 Mio. EUR

Bargeldquote:

0.88

Umsatzwachstum:

-30.21%

Gewinnwachstum:

-119.66%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

PARADIGM BIOPHARMACEUTICALS, PARADIGM BIOPHARMA, PARADIGM BIO

Letzte Datenerhebung:

04.04.26

>PARADIGM BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 444.91 Mio. St.

Frei handelbar: 85.94%

Leerverk. Aktien: -

Rückkaufquote: 0.1%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 1850.01

KBV: 20.24

PEG-Ratio: -0.03

EV/EBITDA: -

Rentabilität:

Bruttomarge: -161.09%

Gewinnmarge: -59585.74%

Operative Marge: -63782.77%

Managementeffizenz:

Gesamtkaprendite: -123.37%

Eigenkaprendite: -180.22%

>PARADIGM BIO Peer Group

Gesundheit

>PARADIGM BIO Chart & Kurs - Stuttgart

>PARADIGM BIO News

02.04.26 - 06:30	With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London (Market Herald)
	Paradigm Biopharma (ASX:PAR) has this week hit two big items out the…...

31.03.26 - 03:30	Investors will get interim results from Paradigm’s Phase III study in Q3 of this year (Market Herald)
	Paradigm Biopharma (ASX:PAR) has officially passed a milestone that gives investors in…...

20.03.26 - 02:30	Paradigm Biopharma activates Hong Kong trial site for Phase III osteo trial for iPPS (Market Herald)
	Paradigm Biopharmaceuticals (ASX:PAR) has kicked off the screening process for participants with…...

19.03.26 - 01:00	The biotech inflection point, and why it′s a ‘grand final’ for Paradigm Biopharma in CY26 (Market Herald)
	The step from 'science project' to commercial asset in the ASX-listed biotechnology…...

23.02.26 - 14:15

XFRA: MWBMU: ENDE DER HANDELSUNTERBRECHUNG FUER DIV. WERTPAPIERE - TEIL 1 (XETRA)

Der Handel in den vom Quoteverpflichteten MWBMU (MWB FAIRTRADE WERTPAPIERHANDELSBANK AG) in den folgenden betreuten Wertpapieren wird ab sofort wieder aufgenommen. Sollten Sie Rueckfragen haben, wenden Sie sich bitte an Cash Markets Operations unter der Telefonnummer +49-69-211-11400. ARP125991090 AU0000003PL9 AU00000088E2 AU000000ALI3 AU000000AMN1 AU000000ANZ3 AU000000APE3 AU000000ASX7 AU000000BWP3 AU000000CAY9 AU000000CG18 AU000000DCC9 AU000000EGH7 AU000000ERA9 AU000000GMD9 AU000000GMG2 AU000000IMU9 AU000000IPD8 AU000000LIN6 AU000000LKO0 AU000000LLC3 AU000000LTR4 AU000000OFX5 AU000000PAR5 AU000000PNN7 AU000000RAC3 AU000000SGM7 AU000000TEG2 AU000000TLX2 AU000000ZNC9 AU0000012056 AU0000024275 AU0000026122 AU0000028367 AU0000058943 AU0000066508 AU0000079212 AU0000081341 AU0000088064 AU0000106643 AU0000118796 AU0000119307 AU0000122251 AU0000129496 AU0000134694 AU0000141533 AU0000150351 AU0000150526 AU0000150898 AU0000153215 AU0000157075 AU0000157455 AU00...

23.02.26 - 09:51

XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 6 (XETRA)

SE0016797773 US5904794089 KYG8879R1048 GB00B0WJ3L68 US4385651033 US6067694041 US83600C3016 US5797801074 US60272J1034 KYG1821D1097 US6025663096 US5949728878 US5949728795 US5949728613 US5949728530 US60649T1079 KYG9891U1334 US74767N1072 CA57773Y2096 US14167R3084 US6067991041 MX01AM050019 BMG210A71016 AU000000GMG2 GB0033877555 US66980N2036 US00704R1095 JP3778270003 GRS524003001 CA6293521051 CA04017M2031 US74982T1034 CA23344V1085 CA6410701073 US6323471002 CA6261351077 US56624R1086 ID1000186505 CA86332K4000 GB00BNYM9W73 SE0017767031 AU0000253197 GB0006389398 IL0010826357 US60871R1005 SGXE27499115 JP3040880001 CA91016A1084 CA8919571023 US3903207039 IT0005568461 US43010T1043 KYG370481080 GB00BTWSXB68 CA7739151032 CA03967C2076 US87507T1016 AU0000453185 CA2924833023 AU0000226300 AU000000OFX5 CA68621J4019 US65447N1037 CNE100007CV2 SE0017833171 KYG8123S1066 US0389238769 BMG684371393 ID1000165004 SG1Q52922370 SE0015244884 CNE1000070L0 AU000000PAR5...

11.02.26 - 02:48	Paradigm Biopharmaceuticals Publishes Canine Osteoarthritis Study Showing Durable PPS Benefits (Small Caps)
	Paradigm Biopharmaceuticals (ASX: PAR) reports durable 26-week canine OA PPS benefits in peer-reviewed PLOS One, bolstering translational human OA potential....

09.02.26 - 04:00	HotCopper Trends: Resolution Minerals, scandium hits, Paradigm Biopharma and more (Market Herald)
	With more than seven million users on the HotCopper forums, every discussion and speculation…...

09.02.26 - 01:30	Paradigm Biopharmaceuticals to boost oral treatment of osteoarthritis for animals (Market Herald)
	Paradigm Biopharmaceuticals (ASX: PAR) has entered into a binding term sheet with…...

05.01.26 - 00:30	Paradigm Biopharma rolls into CY26 on patient headwinds after hitting 25% recruitment milestone (Market Herald)
	Late-stage drug developer Paradigm Biopharmaceuticals (ASX:PAR) is preparing for a huge CY26…...

10.12.25 - 07:00	HotCopper From The Wire: Paradigm Biopharmaceuticals (PAR) CEO Paul Rennie (Market Herald)
	In this latest episode of HotCopper's longform podcast From The Wire, Senior…...

12.11.25 - 02:30	Paradigm Biopharma engages Danish firm to expand Phase 3 knee OA trial (Market Herald)
	Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical…...

30.09.25 - 04:31	‘We’re a Phase III company now’: HotCopper users bullish as Paradigm kicks off major osteo trial (Market Herald)
	Paradigm Biopharma (ASX:PAR) has officially kicked off its final-stage Phase 3 trial…...

01.07.25 - 04:01	Paradigm unlocks $40M loan – and sees a 75cps price not far away (Market Herald)
	Paradigm Biopharmaceuticals (ASX:PAR) shares were up nearly +25% in morning trades as…...

27.06.25 - 05:01	Paradigm Biopharmaceuticals makes key acquisition moving into FY26 (Market Herald)
	Paradigm Biopharmaceutical (ASX: PAR) has opened the purse strings to pick up…...

26.06.25 - 04:01	Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up (Market Herald)
	Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop –…...

03.06.25 - 05:01	Paradigm activates first Aus site for osteoarthritis drug trials (Market Herald)
	Paradigm Biopharmaceuticals (ASX:PAR) has activated its first Australian clinical site as part…...

21.05.25 - 01:01	This stock could have something close to a cure for osteoarthritis. Don′t let it hide under your nose (Market Herald)
	Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and…...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram